Anti-snoring Treatment Market Size, Share, and Trends 2024 to 2033

Anti-snoring Treatment Market (By Device: Mandible Advancement Devices, Tongue Stabilizing Devices, Nasal Devices, Continuous Positive Airway Pressure Devices, Chin Straps, Others; By Distribution Channel: Hospitals, Clinics, Retail Pharmacies, E-commerce, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : March 2024
  • Report Code : 3918
  • Category : Healthcare

Anti-snoring Treatment Market Size and Growth 2024 to 2033

The global anti-snoring treatment market size was estimated at USD 1.43 billion in 2023 and is predicted to hit around USD 3.18 billion by 2033 with a CAGR of 8.32% from 2024 to 2033.

Anti-Snoring Treatment Market Size 2024 to 2033

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • North America led the global market with the highest market share of 38% in 2023.
  • By device type, the continuous positive airway pressure devices segment held the largest share in 2023.
  • By distribution channel, the E-commerce segment captured the largest share in 2023.

Anti-snoring Treatment Market Size in the U.S. 2024 To 2033

The U.S. anti-snoring treatment market size was valued at USD 380 million in 2023 and is anticipated to reach around USD 850 million by 2033, poised to grow at a CAGR of 8.40% from 2024 to 2033.

Anti-Snoring Treatment Market Size 2024 to 2033

North America led the market with the biggest market share of 38% in 2023, primarily propelled by factors such as the high prevalence of obstructive sleep apnea (OSA) and a well-established network of qualified healthcare professionals specializing in snoring and sleep apnea management. Particularly in the United States, the American Academy of Dental Sleep Medicine (AADSM) plays a crucial role in advancing the field of oral appliance therapy for snoring and sleep apnea. Dentists certified by the AADSM undergo specialized training to deliver effective snoring and sleep apnea solutions through oral appliance therapy, ensuring adherence to rigorous standards and achieving high-quality care and treatment outcomes.

Anti-Snoring Treatment Market Share, By Region, 2023 (%)

With nearly 30 million adults in the U.S. affected by obstructive sleep apnea, there is a significant demand for comprehensive treatment options. While Continuous Positive Airway Pressure (CPAP) therapy remains prevalent, oral appliance therapy has emerged as a favored alternative, offering comfort and convenience to patients who may not tolerate CPAP well. Moreover, in the region’s anti-snoring treatment market, other therapeutic options like positional therapy and upper airway stimulation contribute to the diverse range of solutions available to patients in North America, catering to individual needs and preferences and further bolstering the anti-snoring market in the region.

  • In February 2024, an anti-snoring device developed by a couple from Shelburne is aimed at preserving relationships.

Anti-snoring Treatment Market Overview

Snoring in adults poses a common challenge, causing distress for both sufferers and their partners. Effective management necessitates a thorough approach encompassing counseling, diagnostic evaluation, and tailored treatment. While evidence-based recommendations exist for certain scenarios, the overall state of evidence for many diagnostic and therapeutic techniques still needs to be improved. Diagnosis typically involves patient history and clinical examination, with polysomnography serving as the gold standard, supplemented by cardiorespiratory polygraphy when warranted.

Conservative measures such as positional therapy and weight reduction are recommended, although the efficacy of myofascial therapies remains uncertain. Mandibular advancement devices offer a potential instrument-based treatment option for suitable cases. Surgical intervention may be necessary in the presence of concomitant nasal breathing impairment or suspected soft palate abnormalities, with procedures tailored to individual anatomical suitability. It's important to emphasize that snoring, as per this guideline, is not considered a disease, and treatment is pursued only at the patient's discretion, underscoring the significance of a patient-centered approach in decision-making.

  • In January 2024, DeRucci introduced its new line of sleep health technologies, which includes smart sleep products such as a smart mattress, an intelligent height-adjustable pillow, AI sleep monitoring, intelligent voice control panels, and curtain tracks.

Growth Factors

The introduction of 3D digital scanning technology allows for the precise design and fabrication of oral appliances tailored to each individual's unique oral anatomy. These personalized appliances effectively reduce snoring and alleviate obstructive sleep apnea, significantly enhancing sleep quality. This innovation drives the growth of the anti-snoring treatment market by meeting the increasing demand for customized solutions in sleep disorder treatment.

The anti-snoring treatment market experiences growth as healthcare providers increasingly rely on specialized sleep studies and evidence-based recommendations for diagnosing and treating snoring. With a focus on conservative treatments like positioning therapy and weight loss, there's a growing emphasis on comprehensive care, attracting more patients seeking effective solutions and driving market expansion.

As awareness of MAS therapy grows and its efficacy becomes more widely recognized, there is considerable potential for the anti-snoring treatment market expansion and increased adoption among individuals seeking alternative treatments for snoring and sleep apnea.

A novel approach to preventing snoring through posture adjustment during sleep shows promising results. By widening the oropharynx space through cervical spine expansion and dedicated pillows with adjustable angles, this method offers a non-invasive yet effective solution. Such innovative products cater to consumer preferences for comfortable and user-friendly interventions, stimulating market growth.

Anti-snoring beds emerge as a valuable alternative to traditional positional therapy, providing varying angles to optimize airway alignment during sleep. Studies indicate higher success rates in snoring cessation with larger angle interventions, driving demand for these specialized beds and contributing to the expansion of the anti-snoring treatment market.

Anti-snoring Treatment Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 8.32%
Global Market Size in 2023 USD 1.43 Billion
Global Market Size by 2033 USD 3.18 Billion
U.S. Market Size in 2023 USD 380 Million
U.S. Market Size by 2033 USD 850 Million
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Device and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Anti-snoring Treatment Market Dynamics

Drivers

Rising awareness

As awareness of the health risks associated with sleep apnea grows, demand for effective treatment solutions escalates. Surgical interventions and dental devices emerge as key treatment approaches, targeting anatomical causes of snoring to improve airflow in the airway during sleep. This heightened focus on treatment options propels the expansion of the anti-snoring treatment market, presenting opportunities for growth and innovation in the healthcare industry.

  • The National Healthy Sleep Awareness Project highlights snoring as a crucial indicator of obstructive sleep apnea, a prevalent chronic condition affecting approximately 30 million adults in the U.S.

Addressing the global rise in sleep disorders

Despite the widespread impact of sleep disorders worldwide, there is a significant gap in recognition and treatment within clinical practice. This underlines the urgent need for accessible and effective solutions to address sleep-related issues. As awareness grows regarding the crucial role of quality sleep in overall health, there's a rising demand for interventions, driving the expansion of the anti-snoring treatment market. This presents a lucrative opportunity for healthcare providers and innovators to meet the unmet needs of diverse populations and drive meaningful growth in the industry.

  • The prevalence of chronic insomnia in the United States alone ranges from 9% to 19%, with higher rates reported among women, minorities, and the elderly, reaching approximately 50%.

Restraints

Challenges and constraints in surgical management of snoring and sleep apnea

The effectiveness and safety of surgical interventions for snoring and sleep apnea, notably laser-assisted uvulopalatoplasty and radiofrequency ablation are hindered by limited evidence stemming from small-scale randomized controlled trials. These studies fail to demonstrate significant improvements in key outcomes such as daytime sleepiness, quality of life, apnea reduction, or snoring.

Procedures like uvulopalatopharyngoplasty pose a notable risk of long-term side effects, notably difficulty swallowing, resulting in reduced optimism for the anti-snoring treatment market. Given these constraints, there is a critical need for further research, particularly randomized controlled trials, to explore alternative surgical approaches with a focus on efficacy and safety beyond conventional methods, aiming to enhance treatment options and patient care in this domain.

Side effects

The prevalence of side effects, such as short-term facial muscle problems and dental issues, presents a challenge to the widespread adoption of anti-snoring treatments, particularly mandibular advancement devices (MAS). While these side effects are often minor, they can impact patient comfort and satisfaction. Balancing the efficacy of MAS in treating snoring and obstructive sleep apnea (OSA) against these potential drawbacks is crucial. However, the existence of side effects may deter some individuals from seeking or adhering to treatment, thereby limiting the growth potential of the anti-snoring treatment market.

Opportunities

Mandibular advancement splints

Mandibular advancement splint (MAS) therapy emerges as a leading alternative to continuous positive airway pressure (CPAP) for obstructive sleep apnea treatment. Functioning akin to a mouth guard, when properly fitted, MAS effectively reduces snoring by advancing the mandible relative to the maxilla, thus widening the airway and minimizing collapsibility. This innovative oral appliance offers a promising opportunity within the anti-snoring treatment market, providing patients with a comfortable and effective solution to address sleep-related breathing disorders.

Advancing personalized treatment

In the anti-snoring treatment market, the evolution towards personalized medicine in obstructive sleep apnea (OSA) treatment underscores the need to acknowledge individual variability among patients. Recent progress in addressing the heterogeneity of OSA signals a promising shift towards precision sleep medicine. However, the reliance on continuous positive airway pressure (CPAP) therapy, coupled with challenges related to patient tolerance, necessitates the exploration of alternative treatment options.

With limited personalization in OSA therapy currently practiced in clinical settings, there exists a significant opportunity for innovation within the anti-snoring treatment market. By developing tailored solutions that address individual patient needs and preferences, providers can capitalize on this growing demand for personalized approaches to OSA management, driving market growth and enhancing patient outcomes.

Device Insights

The continuous positive airway pressure devices segment held the largest share in 2023. This segment offers vital solutions for maintaining open breathing airways during sleep through mild air pressure delivery. Widely prescribed for sleep-related breathing disorders like sleep apnea and beneficial for preterm infants with underdeveloped lungs, CPAP therapy provides numerous health advantages, including the prevention or control of high blood pressure, stroke risk reduction, and cognitive function enhancement.

CPAP machines deliver a steady airflow to prevent airway collapse, thereby improving sleep quality, albeit initial usage discomforts like congestion and dry mouth may occur. While CPAP remains the primary therapy, tailored recommendations from sleep specialists may lead to the adoption of alternative Positive Airway Pressure (PAP) devices based on individual circumstances, emphasizing the importance of understanding diverse offerings in the anti-snoring treatment market.

  • In June 2022, we saw the launch of a new anti-snoring device (ASD) by Illusion Aligners. This oral device is designed for ease of use, effectiveness, and comfort.

Distribution Channel Insights

The e-commerce segment captured the largest share in the anti-snoring treatment products in 2023, offering a convenient platform for consumers to access a variety of brands such as AddBeauty, Digital Shoppy, Tirthtreads, and Onsafe (Nasal Strips). Digital Shoppy's snoring aids, made of silicone and plastic with embedded magnets to open nasal passages, promise side-effect-free relief. At the same time, Tirthtreads provides nose clips in a protective case for comfortable insertion into nostrils.

Increased online accessibility allows individuals to address snoring concerns conveniently, with many products boasting non-toxic materials and breathability. Moreover, innovations like smartphone application-administered upper airway training offer promising alternatives to traditional remedies, highlighting the evolving anti-snoring treatment market through e-commerce platforms.

Recent Developments

  • In December 2022, Mindray announced the launch of its wearable patient monitoring device, the mWear system, designed to track vital signs and ensure efficient patient care and workflow.
  • In July 2022, Glidewell launched a new addition to its portfolio of mandibular advancement devices, the Silent Nite Sleep Appliance with Glidewell Hinge. The device is used to treat snoring and obstructive sleep apnea (OSA).

Anti-snoring Treatment Market Companies

  • Apnea Sciences Corp.
  • SomnoMed Ltd.
  • Airway Management, Inc.
  • ResMed Inc.
  • Fisher & Paykel Healthcare Corp. Ltd.
  • Koninklijke Philips NV
  • Sleep Well Enjoy Life, Ltd.
  • Tomed Dr. Toussaint GmbH
  • MEDiTAS Ltd.

Segments Covered in the Report

By Device

  • Mandible Advancement Devices
  • Tongue Stabilizing Devices
  • Nasal Devices
  • Continuous Positive Airway Pressure Devices
  • Chin Straps
  • Others 

By Distribution Channel

  • Hospitals
  • Clinics
  • Retail Pharmacies
  • E-commerce
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

The global anti-snoring treatment market size is expected to increase USD 3.18 billion by 2033 from USD 1.43 billion in 2023.

The global anti-snoring treatment market will register growth rate of 8.32% between 2024 and 2033.

The major players operating in the anti-snoring treatment market are Apnea Sciences Corp., SomnoMed Ltd., Airway Management, Inc., ResMed Inc., Fisher & Paykel Healthcare Corp. Ltd., Koninklijke Philips NV, Sleep Well Enjoy Life, Ltd., Tomed Dr. Toussaint GmbH, MEDiTAS Ltd., and Others.

The driving factors of the anti-snoring treatment market are the awareness of the health risks associated with sleep apnea grows and demand for effective treatment solutions escalates.

North America region will lead the global anti-snoring treatment market during the forecast period 2024 to 2033.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anti-snoring Treatment Market 

5.1. COVID-19 Landscape: Anti-snoring Treatment Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anti-snoring Treatment Market, By Device

8.1. Anti-snoring Treatment Market, by Device, 2024-2033

8.1.1. Mandible Advancement Devices

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Tongue Stabilizing Devices

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Nasal Devices

8.1.3.1. Market Revenue and Forecast (2021-2033)

8.1.4. Continuous Positive Airway Pressure Devices

8.1.4.1. Market Revenue and Forecast (2021-2033)

8.1.5. Chin Straps

8.1.5.1. Market Revenue and Forecast (2021-2033)

8.1.6. Others

8.1.6.1. Market Revenue and Forecast (2021-2033)

Chapter 9. Global Anti-snoring Treatment Market, By Distribution Channel

9.1. Anti-snoring Treatment Market, by Distribution Channel, 2024-2033

9.1.1. Hospitals

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Clinics

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Retail Pharmacies

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. E-commerce

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. Global Anti-snoring Treatment Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Device (2021-2033)

10.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Device (2021-2033)

10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Device (2021-2033)

10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Device (2021-2033)

10.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Device (2021-2033)

10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Device (2021-2033)

10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Device (2021-2033)

10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Device (2021-2033)

10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Device (2021-2033)

10.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Device (2021-2033)

10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Device (2021-2033)

10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Device (2021-2033)

10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Device (2021-2033)

10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Device (2021-2033)

10.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Device (2021-2033)

10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Device (2021-2033)

10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Device (2021-2033)

10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Device (2021-2033)

10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Device (2021-2033)

10.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Device (2021-2033)

10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Device (2021-2033)

10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)

Chapter 11. Company Profiles

11.1. Apnea Sciences Corp.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. SomnoMed Ltd.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Airway Management, Inc.

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. ResMed Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Fisher & Paykel Healthcare Corp. Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Koninklijke Philips NV

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Sleep Well Enjoy Life, Ltd.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Tomed Dr. Toussaint GmbH

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. MEDiTAS Ltd.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client